AZ shows better asthma control
New study shows Symbicort adjustable dosing provides better asthma control AstraZeneca has presented data that show the rate of severe exacerbations is 40% lower in asthma patients on Symbicort adjustable dosing than in patients on Seretide fixed dosing. These are the first head-to-head data on the two fastest growing brands in asthma treatment.
New study shows Symbicort adjustable dosing provides better asthma control AstraZeneca has presented data that show the rate of severe exacerbations is 40% lower in asthma patients on Symbicort adjustable dosing than in patients on Seretide fixed dosing. These are the first head-to-head data on the two fastest growing brands in asthma treatment.
'Symbicort is unique in that it is the only combination treatment for asthma that enables patients to improve their lung function and reduce exacerbations and symptoms by adjusting their dose according to the variations in the disease, said Dr Anders Ekblom, vice president & head of the respiratory & inflammation therapy area, AstraZeneca. 'These results will help to continue the growth of Symbicort in the marketplace (+79% CER in the first half of 2003) and establish it as an excellent choice for the management of a chronic and variable disease like asthma.'